Can an MRI model predict cancer progression? A 33-patient holdout is promising, not treatment guidance
A Chinese single-centre model separated progression risk after chemoradiotherapy in 113 patients, but the holdout contained only 33 people and no external hospital. The paper's feature count is also internally inconsistent.
The short version
- What happened
- Researchers retrospectively analysed 113 patients from one Shandong hospital: 80 for model development and 33 for a held-out internal test.
- Who it affects
- People facing a rare head-and-neck cancer need better estimates of progression risk, but a model should not determine treatment intensity or follow-up until another hospital can reproduce the predictions and show that using them improves decisions without avoidable harm.
- What remains unproven
- Retrospective single-centre cohort
Keep in mind
Retrospective single-centre cohort
113 patients total
33-patient internal holdout
No external validation
No prospective decision test
One MRI sequence and scanner context
Feature-count inconsistency in the paper
No demonstrated patient benefit
Source analysis · 1 linked source. Primary analysed source date: 28 October 2026.
Read the full report · 3 min The evidence, methods, implications and limitations
The model found a signal in pretreatment MRI
Researchers used records from 113 people with hypopharyngeal squamous-cell cancer treated with concurrent chemoradiotherapy at one Shandong hospital between 2016 and 2019. They developed the model in 80 patients and reserved 33 for a final internal test. Two experienced radiologists outlined tumours on diffusion-weighted MRI, from which the team extracted 1,288 image features.
A radiomics score alone produced validation AUCs of 0.737 for one-year and 0.715 for two-year progression-free survival. Combining the score with age and tumour T stage yielded a reported validation C-index of 0.858, but the confidence interval was 0.690 to 1.000. High- and low-risk groups also differed in the holdout set at p=0.023.[1]
The study cannot support changing treatment or follow-up
The holdout came from the same hospital, scanner family and historical care pathway as the training data. Thirty-three patients are too few to establish calibration, subgroup performance or transport to another clinic. The study did not compare model-guided care with usual practice and measured no benefit from adding immunotherapy, intensifying chemotherapy or changing scan intervals.
Reproducibility also needs clarification: the abstract and results say six radiomic features were selected, while the published coefficient table lists seven. The authors acknowledge the single-centre, retrospective design, small sample and use of one MRI sequence. A preregistered external validation with locked code and treatment-independent evaluation would change the assessment.[1]
The distinction that matters
What was tested—and what was not
The paper tests prediction inside one historical dataset, not a clinical decision pathway.
Develop
Select features in 80 patients
Training-only preprocessing and cutoff
Hold out
Test in 33 patients from the same hospital
C-index 0.858; wide uncertainty
Missing
Use the score to change care prospectively
No treatment or patient-outcome evidence